No Data
Regent Pacific Properties Reports Increased Financial Performance for 2024
Regent Pacific to Settle Loan Through Share Issue
REGENT PACIFIC plans to issue approximately 63.3772 million capitalized shares to the controlling Shareholder.
REGENT PACIFIC (00575) announced that on April 7, 2025, the company (as the issuer) entered into a debt settlement agreement with Galloway (as the subscriber), wherein the company intends to issue 63,377,163 capitalized shares to the subscriber at a capitalization price of HKD 0.485 per share. The total capitalization price payable for all capitalized shares by the subscriber will be settled at completion through the capitalization and offsetting of a loan and accrued interest amounting to USD 3,956,484 (approximately HKD 30,737,924.20). It is reported that the subscriber provided a loan to the group to ...
REGENT PACIFIC (00575.HK) entered into a debt settlement agreement with Galloway.
On April 7, Glorious Resources announced that REGENT PACIFIC (00575.HK) entered into a debt conversion agreement with Galloway (as the subscriber) on April 7, 2025. According to this agreement, the parties conditionally agree that the subscriber will subscribe for and the company will allot and issue a total of 63.377 million capitalized shares, with a capitalization price of HKD 0.485 per capitalized share. The total capitalization price payable by the subscriber for all capitalized shares will be settled upon completion through the capitalization and offset of a loan and accrued interest of USD 3,956,484. The capitalized shares are equivalent.
Express News | Regent Pacific Group Ltd - Shall Allot and Issue 63.4 Mln Capitalisation Shares at HK$0.485 per Share
REGENT PACIFIC (00575.HK) expects a significant reduction in the shareholder loss for the year 2024 compared to last year.
On March 27, Gelonghui reported that REGENT PACIFIC (00575.HK) announced its annual performance, with the company's loss attributable to shareholders significantly reduced compared to last year, approximately 4.48 million USD, primarily due to the group's operational and R&D expenses of about 4.99 million USD. The year 2024 marks a time of strategic progress for the company, signifying the achievement of several important milestones in its strategic journey. The company's commercial strategic partner, Jiangsu Wanbang Pharmaceutical, submitted a new drug application to the National Medical Products Administration of China by the end of the year. In addition, Jiangsu Wanbang Pharmaceutical received confirmation from the National Medical Products Administration on March 24, 2025.
